摘要
目的研究重组人血管内皮抑制素注射液（恩度）联合化疗治疗中晚期非小细胞肺癌的临床效果。方法研究年度2015年1月~2015年12月,纳入中晚期非小细胞肺癌共47例,抽签法分组。接受化疗者有23例,入对照组;接受恩度联合化疗者有24例,入实验组。组间比较。结果 2组中实验组临床有效率更高,KPS改善率更高,有统计学意义（P〈0.05）。结论恩度联合化疗治疗中晚期非小细胞肺癌效果佳,临床有效率高。
Objective Clinical effect of human recombinant endostatin injection（endostar）combined with chemotherapy in treatment of middle-advanced non-small cell lung cancer is to be studied. Methods Chose 47 patients of middle-advanced non-small cell lung cancer who were treated in hospital from January 2015 to December 2015 and separated them into two groups by drawing lottery,23 patients in control group were given chemotherapy treatment,while another 24 patients in study group were given endostar combined with chemotherapy treatment,and then compared patients’ treatment effects between two groups. Results Patients’ clinical treatment efficiency was much higher and their KPS improvements were much better in study group compared to counterparts in control group. there was a differential between two groups and such a differential had statistic value（P 〈 0.05）. Conclusion Endostar combined with chemotherapy is much more clinically effective in treatment of middle-Advanced non-small cell lung cancer.
出处
《中国卫生标准管理》
2016年第7期78-79,共2页
China Health Standard Management
关键词
中晚期非小细胞肺癌
恩度
化疗
Middle-advanced non-small cell lung cancer
Endostar
Chemotherapy
